Patents Examined by William Moore
-
Patent number: 9200239Abstract: Subtilase variants having an improved wash performance on egg stains. These subtilases are useful exhibiting excellent or improved wash performance on egg stains when used in e.g. cleaning or detergent compositions, such as laundry detergent compositions and dish wash compositions, including automatic dish wash compositions.Type: GrantFiled: June 5, 2014Date of Patent: December 1, 2015Assignee: Novozymes A/SInventors: Stefan Minning, Jurgen Carsten Franz Knotzel, Niels Henrik Sorensen
-
Patent number: 6665833Abstract: In a turbo coder, rate conversion and/or rate matching is achieved by deleting parity bits P1 and P2 from the outputs of two constituent coders, one supplied with data bits to be coded and the other supplied with the same data bits after interleaving. Deleted bits are determined by a rate matching control unit directly for the P1 bits and via a similar position interleaving step for the P2 bits. A similar rate matching arrangement is provided for only two of the three outputs of a rate ⅓ convolutional coder, the third output corresponding to a strongest coding polynomial in terms of minimum free distance and none of its coded data bits being deleted.Type: GrantFiled: June 19, 2000Date of Patent: December 16, 2003Assignee: Nortel Networks LimitedInventors: Wen Tong, Stephan Gosne, Catherine Leretaille (formerly Gauthier), Frederic Gabin
-
Patent number: 6651199Abstract: A trigger circuit for an In-System Programmable (ISP) memory device that operates with a JTAG interface. The trigger circuit receives instruction signals from the JTAG control circuitry, and limits the duration of these instruction signals to avoid erroneously repeating ISP programming operations. The trigger circuit includes a first logic circuit, a delay circuit, and a second logic circuit. The first logic circuit generates a logic high output when both the JTAG RUN-TEST and a program instruction signal are simultaneously asserted, and causes the second logic circuit to toggle the limited duration instruction signal into a logic high state. The delay circuit also detects the simultaneous assertion of the JTAG RUN-TEST and a program instruction signal, and generates a cancellation signal after a predetermined number of clock cycles. The cancellation signal causes the second logic circuit to toggle the limited duration instruction signal into a logic low state.Type: GrantFiled: June 22, 2000Date of Patent: November 18, 2003Assignee: Xilinx, Inc.Inventor: Farshid Shokouhi
-
Patent number: 6611942Abstract: The present invention concerns a method of protecting the transmission of cells in a telecommunication system, the method consisting, on the transmitter side, of simultaneously transmitting two identical flows of cells on two distinct physical links and, on the receiver side, of receiving each of the two flows of cells respectively transmitted on the said two links and selecting one of them. The method further consists, on the transmitter side, of inserting, regularly in each of the flows, cells serving as markers and thus delimiting blocks of cells or sets of blocks of cells, and, on the receiver side, of selecting, block after block or group of blocks after group of blocks, the block or group of blocks from the flow of cells which has the fewer transmission errors compared with the block or group of blocks of the same order number in the other flow.Type: GrantFiled: June 19, 2000Date of Patent: August 26, 2003Assignee: France Telecom SAInventors: Patrick Battistello, Andre Jaillard
-
Patent number: 6180361Abstract: The present invention provides DNA compounds that encode the expandase/hydroxylase enzyme of Cephalosporium acremonium. The compounds can be used to construct recombinant DNA expression vectors for a variety of host cells, including E. coli, Penicillium, and Cephalosporium.Type: GrantFiled: December 12, 1988Date of Patent: January 30, 2001Assignee: Eli Lilly and CompanyInventors: Thomas D. Ingolia, Stephen W. Queener, Suellen M. Samson, Paul L. Skatrud
-
Patent number: 6143289Abstract: Described are preferred processes for suppressing proliferation of or for myeloprotecting myeloid cells in mammals. The processes involve the use of chemokines of the group Macrophage Inflammatory Protein-2.alpha. (MIP-2.alpha.), Platelet Factor 4 (PF4), Interleukin-8 (IL-8) and Macrophage Chemotactic and Activating Factor (MCAF), or involve the use of these chemokines or Macrophage Inflammatory Protein-1.alpha. (MIP-1.alpha.) in synergistic combinations or while they are substantially completely in monomeric form (i.e. substantially free from their polymerized or aggregated forms).Type: GrantFiled: December 9, 1992Date of Patent: November 7, 2000Assignee: Indiana University FoundationInventors: Hal E. Broxmeyer, Scott Cooper, Charles Mantel, Li Lu
-
Patent number: 5945510Abstract: A substantially pure mammalian protein, hereinafter "zonulin", that is a physiological modulator of mammalian tight junctions is disclosed, as well as methods for the use of the same.Type: GrantFiled: May 21, 1997Date of Patent: August 31, 1999Assignee: University of Maryland, BaltimoreInventor: Alessio Fasano
-
Patent number: 5854396Abstract: A novel protein having inhibitory activity on the protease activity of hepatocyte growth factor (HGF) activator was purified and isolated, and its molecular weight (ca. 30,000 daltons) and partial amino acid sequence were determined. A gene coding for the protein was cloned, and the gene DNA was incorporated into a vector, for transforming host cells. Cultivation of the transformant gave the desired protein. The protein can be used as an in vivo or in vitro control factor for HGF or HGF activator. It is also useful as an antigen to be used in producing an antibody to be used as means for kinetic studies of the protein, or as a standard in assay systems therefor.Type: GrantFiled: November 19, 1997Date of Patent: December 29, 1998Assignee: Mitsubishi Chemical CorporationInventors: Takeshi Shimomura, Toshiya Kawaguchi, Naomi Kitamura
-
Patent number: 5196317Abstract: The invention relates to a process for achieving high, thermally-induced expression rates, which last for a relatively long period of time, of proteins in recombinant cells, preferably in E. coli cells, by optimizing cell density, induction temperature and supplemented amino-acid-containing substrates.Type: GrantFiled: November 2, 1990Date of Patent: March 23, 1993Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Martin Heinrich, Wolfgang Ebeling, Wolfgang Brummer